Skip to content
Thursday, March 13, 2025
GLP-1 Watch
All the latest news and updates about GLP-1 Drugs
Search
Search
Privacy Policy
The Evolving Landscape of GLP-1 Drugs: Innovations, Market Trends, and Health Implications
Home
2025
March
2
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
GLP-1 News
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
March 2, 2025
admin
The CHMP has recommended the approval of AbbVie’s upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA).
Post navigation
FDA accepts Sobi’s Gamifant application for HLH/MAS treatment
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects – LINK nky